Acrivon Therapeutics, Inc. (ACRV)
$0.00+$0.00 (+0.00%) TodayExtended Hours
Mary Miller - OfficerAcrivon Therapeutics Inc is a clinical-stage biopharmaceutical company developing oncology medicines that the Firm matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's pipeline includes ACR-368, referred to as prexasertib, a targeted oncology asset, as well as preclinical stage pipeline programs targeting critical nodes in the DNA Damage Response and cell cycle regulation pathways, including WEE1, a protein kinase, and PKMYT1; ACR-2316 a selective, dual WEE1/PKMYT1 inhibitor; and ACR-6840, a development candidate targeting CDK11. It has one reportable segment focused on the research and development of precision oncology therapies.
| Form 4 transaction type | Transactions | Shares | Total value |
|---|---|---|---|
| Open-market sale | 9 | 18,754 | $40K |
| Grant or award | 7 | 141,925 |
Dollar totals are shown for open-market purchases and sales only. Grants, option exercises, gifts and tax withholding are reported by share count because they are not trades at a market price.
88 Form 4 filings on record, the earliest from Oct 3, 2024, newest first. Filing history page 1 of 3.
| Date | Insider | Transaction | Security | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Peter Blume-Jensen - Officer | Open-market sale | Common Stock | 14,036 | $2.21 | $31K | |
| Katharine Peterson - Officer | Open-market sale | Common Stock | 101 | $2.01 | $203 | |
| Mary Miller - Officer | Open-market sale | Common Stock | 185 | $2.01 | $372 | |
| Erick Gamelin - Officer | Open-market sale | Common Stock | 400 | $2.01 | $804 | |
| Eric Devroe - Officer | Open-market sale | Common Stock | 604 | $2.01 | $1K | |
| Peter Blume-Jensen - Officer | Open-market sale | Common Stock | 1,229 | $2.01 | $2K | |
| Peter Blume-Jensen - Officer | Open-market sale | Common Stock | 484 | $2.01 | $973 | |
| Adam D. Levy - Officer | Open-market sale | Common Stock | 1,142 | $1.57 | $2K | |
| Mary Miller - Officer | Open-market sale | Common Stock | 573 | $1.76 | $1K | |
| RA CAPITAL MANAGEMENT, L.P. | Grant or award | Stock Option (Right to Buy) | 20,275 | $0.00 | - | |
 Michael John Tomsicek | Grant or award | Stock Option (Right to Buy) | 20,275 | $0.00 | - | |
| Sharon Shacham | Grant or award | Stock Option (Right to Buy) | 20,275 | $0.00 | - | |
 Santhosh Palani | Grant or award | Stock Option (Right to Buy) | 20,275 | $0.00 | - | |
| Ivana Magovcevic-Liebisch | Grant or award | Stock Option (Right to Buy) | 20,275 | $0.00 | - | |
| Derek Dirocco | Grant or award | Stock Option (Right to Buy) | 20,275 | $0.00 | - | |
| Charles M. Baum | Grant or award | Stock Option (Right to Buy) | 20,275 | $0.00 | - | |
| Peter Blume-Jensen - Officer | Tax withholding / forfeiture | Common Stock | 13,729 | $1.79 | $25K | |
| RA CAPITAL MANAGEMENT, L.P. | Grant or award | Common Stock | 9,366 | $0.00 | - | |
| Michael John Tomsicek | Grant or award | Common Stock | 9,366 | $0.00 | - | |
| Sharon Shacham | Grant or award | Common Stock | 9,366 | $0.00 | - | |
| Santhosh Palani | Grant or award | Common Stock | 9,366 | $0.00 | - | |
| Ivana Magovcevic-Liebisch | Grant or award | Common Stock | 9,366 | $0.00 | - | |
| Derek Dirocco | Grant or award | Common Stock | 9,366 | $0.00 | - | |
| Charles M. Baum | Grant or award | Common Stock | 9,366 | $0.00 | - | |
| Katharine Peterson - Officer | Grant or award | Common Stock | 14,227 | $0.00 | - | |
| Mansoor Raza Mirza - Officer | Grant or award | Common Stock | 38,817 | $0.00 | - | |
| Mary Miller - Officer | Grant or award | Common Stock | 49,830 | $0.00 | - | |
| Adam D. Levy - Officer | Grant or award | Common Stock | 46,167 | $0.00 | - | |
| Erick Gamelin - Officer | Grant or award | Common Stock | 38,584 | $0.00 | - | |
| Eric Devroe - Officer | Grant or award | Common Stock | 72,981 | $0.00 | - | |
| Peter Blume-Jensen - Officer | Grant or award | Common Stock | 180,095 | $0.00 | - | |
| Peter Blume-Jensen - Officer | Grant or award | Common Stock | 72,706 | $0.00 | - |
A Form 144 is notice of an INTENDED sale, not a completed one. It often precedes the Form 4 that reports the trade actually happening.
| Filed | Filer | Relationship | Shares | Market value | Notice |
|---|---|---|---|---|---|
| Peter Blume-Jensen | Officer, Director | 14,036 | $31K | View on EDGAR |
Acrivon Therapeutics, Inc. (ACRV) had 15 insider filings in the last 90 days, with the most recent on 2026-08-27. The full record for ACRV runs to 88 Form 4 filings, the earliest from 2024-10-03. InsiderAlpha tracks every Form 4, Form 144, and 8-K filing in real time.
No insider purchases of ACRV were filed in the last 90 days. 3 purchases are on record for this company.
9 insider sales of ACRV were filed in the last 90 days, totaling $40K.
This page tracks ACRV Form 4 insider transactions, Form 144 sale notices, and 8-K material event disclosures in one timeline. Annual 10-K and quarterly 10-Q reports live on the company's SEC EDGAR page.
Create a free InsiderAlpha account and press Watch on this page to add ACRV to your watchlist. A free account also opens the full scored daily plan with every past day and 3 months of price history. No card is required. Sign up at https://insideralpha.ai/register.
Every Form 4 below links to the original document on SEC EDGAR, so the numbers on this page can be checked against the filing they came from.
Real-time Form 4 alerts, AI-scored daily trade ideas and 10b5-1 plan flags.
